论文部分内容阅读
目的:探讨18F-脱氧葡萄糖(18F-FDG)符合线路单光子发射计算机断层显像(SPECT)在淋巴瘤预后评估中的应用价值。方法:回顾分析52例非霍奇金淋巴瘤(NHL)患者治疗前和4程化疗后18F-FDG符合线路SPECT显像结果,治疗后18F-FDG符合线路SPECT显像反应按照完全缓解(CR)、部分缓解(PR)或无反应(NR)评分。联合使用国际预后指数(IPI)和治疗后18F-FDG符合线路显像SPECT反应评估患者的无失败生存率(FFS)。结果:4程化疗后,18F-FDG符合线路显像反应CR的患者34例,2年FFS是75%;PR患者12例,2年FFS是41%,未缓解6例,2年FFS是0,23例患者疾病进展或复发。18F-FDG符合线路显像反应CR、PR和NR的患者之间的FFS明显不同(P<0.01)。将18F-FDG符合线路SPECT显像反应与IPI相联合,至少分为明显不同的4组,联合危险度评分(CRS)0～1(14例患者)2年FFS77%,CRS2～3(26例患者)2年FFS64%,CRS4(8例患者)2年FFS25%和CRS5～6(5例患者)2年FFS为0,4组患者的2年FFS明显不同(P<0.01)。结论:18F-FDG符合线路显像反应为初发的NHL患者提供了较为准确的预后指标。
Objective: To investigate the value of 18F-FDG coincidence SPECT in evaluating the prognosis of lymphoma. Methods: Fifty-two non-Hodgkin’s lymphoma (NHL) patients underwent preoperative and postoperative chemotherapy with 18F-FDG coincidence SPECT imaging. The postoperative 18F-FDG coincidence SPECT imaging was performed according to complete remission (CR) , Partial response (PR) or no response (NR) score. The combined use of the International Prognostic Index (IPI) and post-treatment 18F-FDG coincident imaging SPECT responses evaluated patients for failure-free survival (FFS). Results: After 4 courses of chemotherapy, 34 patients with CR in 18F-FDG line imaging response and 2 years FFS was 75%. In 12 patients with PR, 2 years FFS was 41%, 6 patients did not relieve, 2 years FFS was 0 , 23 patients with disease progression or recurrence. The FFS was significantly different between patients with 18F-FDG coinciding with CR, PR and NR imaging (P <0.01). The 18F-FDG coincidence SPECT imaging was associated with IPI and was divided into at least 4 distinct groups. The 2-year FFS77% and CRS2-3 in 26 patients with CRS 0-1 (14 patients) 2 years FFS64%, CRS4 (8 patients) 2 years FFS25% and CRS5 ~ 6 (5 patients) 2 years FFS was 0, 4 groups of patients 2 years FFS significantly different (P <0.01). Conclusions: 18F-FDG coincidence imaging can provide a more accurate prognostic indicator for NHL patients.